[Treatment of adult diabetes with semi-euglucon (author's transl)].
Results of Trial in General Practice: Semi-Euglucon was tested in a field study by 366 general practitioners in a total of 2037 adult diabetics. The patient collective included primarily first stabilizations (56.5%), i. e. diabetics not previously treated with drugs, then transfers from sulfonyl ureas of the tolbutamide type (26.0%) and from biguanides (17.5%). During the trial period there was a significant improvement in the metabolic condition. The mean daily dose was 1.3 tablets Semi-Euglucon, small differences occurred depending on the nature of the previous treatment. After changing from the sulfonyl ureas glibornuride, glisoxepide or gliquidone the same mean daily dosage of 1.5 tablets/day was required as with the sulfonyl ureas mentioned--with considerable improvement in the metabolism.
D000368:Aged; D001835:Body Weight / Q000187:drug effects; D003920:Diabetes Mellitus / Q000178:diet therapy / Q000188:drug therapy*; D004038:Diet, Reducing; D004341:Drug Evaluation; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D005905:Glyburide
Die Behandlung des Erwachsenen-Diabetes mit Semi-Euglucon.